Significant factors associated with MetS at enrolment into SLICC–RAS in age, ethnicity and gender-adjusted analyses
| MetS | ||||
|---|---|---|---|---|
| Yes | No | p Value | OR (95% CI) | |
| Current CS (%) | 193/239 (80.8) | 8250/1255 (67.7) | <0.001 | 1.53 (1.05 to 2.25) |
| Average CS dose, mg (median (IQR)) | 30 (15, 45) | 20 (10, 30) | <0.001 | 1.02 (1.01 to 1.04) |
| Highest CS dose, mg (median (IQR)) | 50 (30, 60) | 30 (20, 50) | <0.001 | 1.00 (1.00 to 1.01) |
| Cumulative CS dose, g (median (IQR)) | 3.1 (1.5, 5.4) | 2.3 (1.0, 4.0) | 0.006 | 1.05 (1.00 to 1.09) |
| Past IV CS (%) | 18/230 (7.8) | 52/1193 (4.4) | 0.03 | 3.22 (1.35 to 7.68) |
| Antimalarial (%) | 123/239 (51.5) | 848/1255 (67.6) | <0.001 | 0.51 (0.38 to 0.67) |
| Immunosuppressant (%) | 140/238 (58.8) | 459/1253 (36.6) | <0.001 | 2.21 (1.63 to 3.00) |
| SLICC-DI ≥1 (%) | 26/95 (27.4) | 91/550 (16.6) | 0.01 | 1.99 (1.16 to 3.40) |
| SLEDAI-2K (mean (SD)) | 6.79 (6.19) | 5.24 (5.25) | <0.001 | 1.05 (1.02 to 1.07) |
| SLEDAI ≥10 (%) | 66/239 (27.6) | 221/1252 (17.7) | 0.001 | 1.73 (1.22 to 2.44) |
| High anti-dsDNA (%) | 101/216 (46.8) | 440/1131 (38.9) | 0.03 | 1.32 (1.00 to 1.82) |
| Thrombocytopenia (%) | 14/206 (6.8) | 30/1107 (2.7) | 0.003 | 2.10 (1.03 to 4.29) |
| Leucopenia (%) | 7/203 (3.5) | 92/1108 (8.3) | 0.02 | 0.33 (0.14 to 0.75) |
| Active renal disease (%) | 94/239 (39.3) | 220/1255 (17.5) | <0.001 | 2.87 (2.05 to 4.02) |
| Past renal disease (%) | 22/239 (9.2) | 69/1255 (5.5) | 0.03 | 1.67 (1.00 to 2.88) |
Variables reflect current exposures, recorded at enrolment.
CS, corticosteroid; DI, damage index; IV, intravenous; MetS, metabolic syndrome; RAS, Registry for Atherosclerosis; SLEDAI, systemic lupus erythematosus disease activity index; SLICC, Systemic Lupus International Collaborating Clinics.